INTRODUCTION:

The act of preventing pregnancy alluded to as contraception. A gadget, a medication, a process, or behaviour might all fall under this category. Contraception gives a woman control over her reproductive health and enables her to participate actively in her family planning. This evaluation will not cover abortionfor the reason that it isn't a method of preventing pregnancy. Contraception is a technical advancement that aims to transcend biology. The twentieth century saw the most important breakthroughs in female reproductive health, with more medical options, gadgets, and even surgeries available. This article will concentrate based on various drugs, technologies, in addition techniques that couples can use to avoid becoming pregnant. It should not concentrate on the many behaviors and barriers that are available.¹

The combination contraceptive vaginal ring CCVR, NuvaRing, Organon International (Oss, Netherlands) is a company based throughout the Great Britain. A novel monthly hormonal contraception device. It comprises of a flexible, soft, transparent ring having a diameter 54 mm and a thickness of 4 mm that is possible easily put into the vaginal canal by the lady herself. The lady removes the ring after 3a few weeks of use, establishing a ring-free week before which withdrawal bleeding is common.²

The development of CVR has resulted a significant number of ways of designs with various ring materials, steroid reservoir systems, and steroids incorporated within the rings. Flexible rings composed mof dimethyl-polysiloxane or ethylene-vinyl-acetate are applied in all CVRs currently explored or used. Either of these polymers are not toxic, non-irritating, and inert, with dimensions (50–61 millimeter outside diameter; 46–51 millimeters internal diameter) that are similar to smallest diaphragm diameter size (60millimeters). Because unlike abdomen, the module features action is solely dependent on sex steroid absorption, with no barrier mechanism in place. Consequently, the CVR must be present touch with the vaginal epithelium but neither in the vaginal area or in the genital area. The lady could be easily insert and use the CVR using this technique.³

History:

The vaginal ring (VR) is a lengthy drug delivery technology that allows medications contained in polymeric matrices to diffuse into the vaginal epithelium.⁴ VRs are transdermal drug delivery devices that distribute medications in a regulated manner for intravaginal injection During an extended amount of time.⁵ VRs deliver sustained, therapeutic doses of medications with lower systemic exposure than oral treatments, likely result in fewer side effects. They escape digestibility and first-pass hepatic metabolism.⁴

In Latin American countries, the United States, and Europe, research also on efficacy of something like the CVR have been conducted, VR have been often used for contraception and estrogen replacement in the treating recent past (CVR).⁵

For the most part ladies were pleased with investigational rings in the clinic and interventional studies; in addition, 85 percent to 90 percent saying they would suggest them to a friend. Qualitative methods are highly adapted to comprehending complicated, in-depth, and multivariate decisions, such as women's contraceptive method choices. We performed a thorough investigation. assessment of existing qualitative studies to identify, define, and summarise self-reported limitations to something and also contribution of woman contraceptive use for pregnancy prevention. We offer our findings on contraceptive rings in the interest of gain a greater comprehension of women's experiences and to recommend areas for future research and advancement.⁶

A constant use of a number of vaginal rings is required, which differs from how CVRs are typically employed. The ring is currently used intermittently, meaning it is removed for 7 days after being in place for 3 weeks. Women who utilise a CVR on a continuous basis will stop having menstrual periods. We need further details about the vaginal ring's acceptance and long-term use.⁵

Table 1: Characteristics of commercially available vaginal rings details about the clinical trials²

Product	Vaginal ring Polymer	Drug	Indications for use; onset of therapy	Development company	Level
Estring	silicone reservoir	17β-estradiol	estrogen treatment; 3 months	Pfizer	Marketed
Nuvaring	EVA reservoir	etonogestrel and Ethinyl estradiol	combination contraception; 3 weeks	Merck Shar and Dohme	Marketed
Femring	siliconereservoir	Progesterone	estrogen treatment substitute; 3 months	Warner Chilcott	Marketed
Progering	siliconematrix	Progesterone	Estrogen treatment substitute; 1 year	Population Council	Marketed
Fertiring	Siliconematrix	Progesterone	doses of hormones and maintaining a pregnancy; 3 months	Population Council	Marketed
Ornibel	EVA and TPUreservoir	Etonogestrel and ethinyl Estradiol	contraception in combination; 21 days	Exeltis Healthcare	Marketed
Annovera	silicone reservoir	Nestorone and Ethinyl estradiol	hormonal supplementation and Pregnancy maintenance; 3 months; 1 year	Population Council	Approved

METHODS:

Study Design: Since the first appearance of NuvaRing in 2001, the total amount of customers has progressively increased, as has medical experience with and understanding of its benefits and drawbacks. The purpose of this research is to examine clinical evidence gained through previous 10 years on efficacy, cycle management, safety, and user satisfaction with this CVR. Relevant papers from 2000 to 2012, the most popular words in English were located using the search terms' contraceptive' and' vaginal ring' or 'PubMed, Medline a wide range of randomised controlled studies accustomed to compile this list. Other trials were discovered after making impact with the NuvaRing producer and researchers. Randomised clinical trials, big studies that are either exploratory and retrospectively on efficacy, cycle control, tolerability, and acceptability, in addition pharmacological and metabolic impacts investigations, were chosen for study.⁷

Important Safety Information: NuvaRing:

· Do not use NuvaRing if you smoke cigarettes and are over age 35. Smoking increases the chance of major patients with cardiovascular problems caused by hormonal contraceptives in combination, such as heart problem, clotting in the blood or a stroke, all of it can potentially fatal. This risk rises as one gets older and smokes more cigarettes.

· Something like a CHC, like as NuvaRing, has a connection to a higher chance a group of significant adverse effects, involving thrombosis, strokes, and heart attacks. NuvaRing This isn't a advised for ladies who have experienced a hysterectomy. A timeline of these diseases or any other condition that leads your blood to rise to clot more easily. The kind of progesterone in NuvaRing may assist in raising the possibility Platelets are blood cells. Compared to other progestins used in reduced birth control tablets. If you begin with taking CHCs and then when you begin either both same or after a month, a separate CHC, or longer of if you don't use it, you run the threat of heart attack is highest.

· NuvaRing is just not advised for ladies who a significant number of estrogens in their bodies BP, Diabetes can cause harm to the kidneys, eyes, nerves, or blood vessels, in addition headaches, liver disease, and liver tumours. If you still have any kind of cancer, susceptible relation with estrogen and progesterone, nor if you're a and might be pregnant, get medical advice immediately.

· NuvaRing isn't a ring provide protection against HIV (AIDS) or sexual and asexual transmitted disease illnesses.

· The most frequently encountered negative impacts that has happened reported NuvaRing users are vaginal irritation and cervix irritation- mood swings (depression); discomfort from the ring; upset stomach; vaginal secretions; body weight; genital irritation, or discomfort; painful menstrual cycles; stomach discomfort, acne, and diminished sexual drive.⁸

Pharmacokinetics and Pharmacodynamics:

The CVR and COCs are distinguished by the persistent release of sex hormones into the circulation within the vaginal epithelium. The bioavailability of the CVR's steroid injections have been when compared to steroid hormones generated by various oral combinations contraceptives 5–7 in several investigations. These studies' findings are summarised in a crossover investigation of 16 healthy women, peak blood concentrations (Cmax) of ENG and EE with the CVR were around 40% and 30% are among the have a COC containing 150g desogestrel (DSG, whose pharmacologically active metabolites is ENG) and 30g EE 6, respectively. When comparing the CVR, to the COC, absolute bioavailability was equivalent Greater for EE, but lower for ENG when measured Using parenteral data as a documentation information a reference (103 percent vs. 79 percent). The systemic exposure to ENG was calculated to hold the position of same for both modes of administration, counting the fact the distinction in ENG daily dose emancipated CVR and the COC (120g vs. 150g, respectively). On the opposite, owing to the distinction in EE daily dose (15g vs. 30g), With the COC, the circulatory sensitivity to EE is twice as great as with the CVR. The CVR's decreased EE exposure could be beneficial explain significantly reduced amounts of sex hormone binding globulin (SHBG) seen after after three weeks of usage compared to three-week period COCs 6 ingestions.

As an instance of dosing error, the ring's effects on corpus luteum were studied. Additionally examined during the research period and for an extra two weeks. Ovulation was reduced throughout the five-week length of CVR use, as measured by follicle alterations (seen by sonography) and progesterone levels, and was similar to that seen during COC consumption. Throughout the trial, levels of luteinizing hormone and progesterone were kept to a minimum. The findings show that after the suggested three weeks of use, one ring can be put to use for an extra two weeks.⁷

Efficacy:

When the first ring was inserted, the participant took a urine pregnancy test to rule out any pregnant women. If pregnancy was suspected during the trial, pregnancy tests were also performed. From the last, treatment cycle, a serum test for -human chorionic gonadotrophin was done. Any pregnancies that occurred all over the research were meticulously documented.⁹

Adverse events:

Headaches, a sore vagina, and vaginal discharge have been the most popular prevalent side effects. These are all of themis unique adverse effects roughly one each and every 20 women. Blood clot in the blood arteries, the lungs, the heart, or the brain. If you take a contraceptive vaginal ring instead of the COC pill, this risk there looks to be slightly higher. Fortunately, there's really one danger negligible, especially when compared to hazards clotting in the bloodstream linked with pregnancy. Your healthcare professional can assist you. Will advise you would not use the ring when they know is a participant in the family is had whatever happened previously as a consequence, more likely for thrombosis to form.¹⁰

At screening, cycles 3, 6, 9, and 13, in addition on early withdrawal the effect blood pressure, heart beat, and length of the examination, in addition body weight were measured. Throughout the experiment, unforeseen circumstances and the utilisation of concomitant medications were reported and recorded. Adverse events were defined as any difficulties that were directly connected to ring use, such as vaginal soreness, coital problems, Expulsion of the gadget and the sensea foreign object. It had also been forbidden to make use of any other sex steroids or medicines that cause steroid metabolism to be disrupted.⁹

Cycle control:

Each subject's there was evidence of vaginal hemorrhaging. on daily diary cards and categorised as spotting (one pad/tampon required each day) or bleeding (two pads/tampons required every day). Withdrawal The term "bleeding" was used. That began or continued during the week without a ring; early or late removal sometime at all during the ring-free week. The term "irregular bleeding" was the a phrase that describes all several kinds of vaginal bleeding.⁹

CONCLUSION:

Planning your family's future contraception aid in the decrease in maternal morbidity consequently, considered preventive medicine. In all therapies related to preventive medicine, whether contraception, hypertension therapy, or prevention of osteoporosis, daily therapeutic regimens are very difficult for patients to maintain. Almost all people modern preventive medicine strategies try to simplify the therapy regimen by dosing at less frequent intervals than daily intervals. Contraception, when considered in this light, should be no different. Consequently, new hormonal contraceptive methods that really are consumer, changeable, and therefore aren't required regular or coital supervision are significant advancements in women's contraception.

CVRsa a large number of options of benefits over OCs, additionally to the ones described above. As opposed to the various concentration that occur with OC usage, CVRs achieve consistent circulation serum concentrations of steroid during use with the establishing a steady state. Furthermore, steroids are absorbed straight into the circulation throughout the epithelium. circulatory system avoids effect of initial pass After absorption of hormones in the woman organism, the liver undergoes synthetic progesterone metabolism. Since then, regardless matter the situation, CVR receives a smaller dose of contraceptive steroids than the OCs, the CVR's bioavailable (area under curve) is higher. CVRs can successfully suppress ovulation (their principal mode of action), thick cervical mucus, and depress the endometrium lining with lower steroid dosages than OCs because of these pharmacologic advantages. The efficiency with which CVRs, especially those containing a progesterone without oestrogen, is aided by the secondary contraceptive influence on the cervical mucus. Furthermore, given the lower corticosteroid dose, CVRs provide superior bleeding reduction than low-dose Ocsbecause of the constant steroid release.

REFERENCE:

1. Oshin Bansode Contraception 26 july; 2021,https://www.statpearls.com/ArticleLibrary/viewarticle/19940

2. Frans Jme Roumen. Review of the combined contraceptive vaginal ring, NuvaRing.National Center for Biotechnology Information journal. 2008; 4(2): 441-51.doi: 10.2147/tcrm.s1964.

3. Bryna Harwood Contraceptive Vaginal Rings the global library of women’s medicine’s welfare of women global health program (ISSN: 1756-2228) 2008; DOI 10.3843/GLOWM.10396 https://www.glowm.com/section-view/heading/Contraceptive%20Vaginal%20Rings/item/ 395#.Yeg31PLhWDY.

4. Griffin B, Ridgeway K, Montgomery E. Vaginal ring acceptability and related preferences among women in low- and middle-income countries: A systematic review and narrative synthesis. 2019 Nov 8; PLoS ONE 14(11): e0224898. https:// doi.org/10.1371/ journal. pone.0224898

5. Céline Schurmans1, Irith De Baetselier, Evelyne Kestelyn A Study to A The ring plus project: safety and acceptability of vaginal rings that protect women from unintended pregnancy. BMC Public Health 2015; 15: 348. DOI 10.1186/s12889-015-1680-y.

6. Sara E. Vargas, Miriam M. Midoun, Melissa Guillen A Study to A Qualitative Systematic Review of Women’s Experiences Using Contraceptive Vaginal Rings: Implications for New Technologies, Guttmacher Institute is collaborating with JSTOR to digitize, preserve and extend access to International Perspectives on Sexual and Reproductive Health, 2019; 45: 25–34, doi:10.1363/45e7619.

7. Frans J. M. E. Roumen∗ and Daniel R. Mishell Jr A Study to AThe contraceptive vaginal ring, NuvaRing (R), a decade after its introduction. Article in The European Journal of Contraception and Reproductive Health Care · 2012Oct; DOI: 10.3109/13625187.2012.713535.

8. Prescription NuvaRing is a flexible birth controlvaginal ring used to prevent pregnancy https://www.nuvaring.com/safety-information/.

9. F J Roumen ¹, D Apter, T M Mulders, T O Dieben. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyloestradiol. National Center for Biotechnology Information journal. 2001 Mar 16; (3): 469-75.doi: 10.1093/humrep/16.3.469.

Received on 29.01.2022 Modified on 10.02.2022

Research J. Science and Tech. 2022; 14(1):73-76.

DOI: 10.52711/2349-2988.2022.00011